Company
Ever Supreme Bio Technology Co. Ltd
Headquarters: Taichung, Taiwan
Employees: 94
Market Cap
TW$14.52 Billion
TWD as of Jan. 1, 2025
US$442.4 Million
Ever Supreme Bio Technology Co. Ltd Categories
Taiwan Healthcare BiotechnologyTaiwan Healthcare Taiwan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Ever Supreme Bio Technology Co., Ltd engages in the research and development of cell gene therapies based on immune cells and stem cells. Its products in development include UMSC01, a drug candidate in Phase 2 clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase 3 clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product in Phase 1 clinical trials for use in the treatment of triple-negative breast cancer; and gene modified mesenchymal stem cells and fucoidan nanoparticles for use in the treatment of malignant tumor. The company was founded in 2016 and is based in Taichung, Taiwan.
Stocks & Indices
Ever Supreme Bio Technology Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6712 wb_incandescent